Literature DB >> 29354206

J Curve in Hypertension.

Tanja Dudenbostel1, Suzanne Oparil2.   

Abstract

The relationship between blood pressure and cardiovascular disease risk among treated hypertensives is J-shaped: risk is increased at high levels of blood pressure, falls in parallel with blood pressure reduction and increases again when blood pressure falls below a nadir (the point at which blood pressure is too low to maintain perfusion of vital organs). Randomized controlled trials of antihypertensive treatment have identified J-shaped relationships between achieved systolic and diastolic blood pressures and all-cause mortality, as well as fatal and nonfatal cardiovascular events, but not stroke or renal outcomes, in the general population of hypertensives and high-risk prehypertensives, particularly in subgroups such as the elderly and those with coronary artery disease, chronic kidney disease, diabetes, left ventricular hypertrophy, and high cardiovascular risk because of multiple comorbidities and concomitant risk factors. Blood pressure targets <130-140/70-85 mm Hg were not beneficial for any outcome except stroke and chronic kidney disease.

Entities:  

Keywords:  Chronic kidney disease; Comorbidities; Coronary artery disease; Diastolic; Elderly; Morbidity; Mortality; Systolic

Year:  2012        PMID: 29354206      PMCID: PMC5772985          DOI: 10.1007/s12170-012-0246-0

Source DB:  PubMed          Journal:  Curr Cardiovasc Risk Rep        ISSN: 1932-9520


  51 in total

1.  Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited.

Authors:  Johannes A N Dorresteijn; Yolanda van der Graaf; Wilko Spiering; Diederick E Grobbee; Michiel L Bots; Frank L J Visseren
Journal:  Hypertension       Date:  2011-11-07       Impact factor: 10.190

2.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

3.  Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).

Authors:  Josep Redon; Giuseppe Mancia; Peter Sleight; Helmut Schumacher; Peggy Gao; Janice Pogue; Robert Fagard; Paolo Verdecchia; Michael Weber; Michael Böhm; Bryan Williams; Khalid Yusoff; Koon Teo; Salim Yusuf
Journal:  J Am Coll Cardiol       Date:  2012-01-03       Impact factor: 24.094

4.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

5.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

6.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.

Authors:  N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh
Journal:  Lancet       Date:  2010-06-26       Impact factor: 202.731

7.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

8.  Lowering blood pressure reduces renal events in type 2 diabetes.

Authors:  Bastiaan E de Galan; Vlado Perkovic; Toshiharu Ninomiya; Avinesh Pillai; Anushka Patel; Alan Cass; Bruce Neal; Neil Poulter; Stephen Harrap; Carl-Erik Mogensen; Mark Cooper; Michel Marre; Bryan Williams; Pavel Hamet; Giuseppe Mancia; Mark Woodward; Paul Glasziou; Diederick E Grobbee; Stephen MacMahon; John Chalmers
Journal:  J Am Soc Nephrol       Date:  2009-02-18       Impact factor: 10.121

9.  Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial.

Authors:  Paolo Verdecchia; Jan A Staessen; Fabio Angeli; Giovanni de Simone; Augusto Achilli; Antonello Ganau; Gianfrancesco Mureddu; Sergio Pede; Aldo P Maggioni; Donata Lucci; Gianpaolo Reboldi
Journal:  Lancet       Date:  2009-08-15       Impact factor: 79.321

10.  The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?

Authors:  L Farnett; C D Mulrow; W D Linn; C R Lucey; M R Tuley
Journal:  JAMA       Date:  1991 Jan 23-30       Impact factor: 56.272

View more
  3 in total

1.  A nationwide assessment of blood pressure control and the associated factors in Chinese type 2 diabetes mellitus patients.

Authors:  Yu-Qing Zhang; Yong Li; Yu-Gang Dong; Yan-Hua Wu; Rui Bian; Ji-Hu Li; Li-Nong Ji
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-10-11       Impact factor: 3.738

Review 2.  Blood pressure j-curve: current concepts.

Authors:  Maciej Banach; Wilbert S Aronow
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

3.  Control of Blood Pressure and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Hernando Vargas-Uricoechea; Manuel Felipe Cáceres-Acosta
Journal:  Open Med (Wars)       Date:  2018-08-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.